Clinical Trial

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Study acronym: ASCEND
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.
Protocol Amendment History 3 changes
notable Trial sites expanded: 22 -> 25 locations 2026-07-22
notable Trial sites expanded: 12 -> 17 locations 2026-06-17
notable Trial sites expanded: 5 -> 8 locations 2026-04-14
Trial Details
NCT Number NCT07335497
Lead Sponsor Crescent Biopharma, Inc.
Conditions Locally Advanced / Metastatic Solid Tumors
Enrollment 290 participants
Start Date 2026-02-17
Primary Completion 2029-02 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-14